AFT Pharmaceuticals Limited updated earnings guidance for the fiscal year 2024. For the year, the company now expected operating profit, including the company's share of the license fee (estimated at NZD 6 million), to range between $23 million to $25 million. AFT's earlier guidance for operating profit of $22 million to $24 million, excluded the Hikma license income and was subject to finalisation of the US commercialisation plans, and the related investment costs, for Maxigesic Rapid, a prescription-only tablet form of the pain relief medicine approved for sale in the US last year.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.09 NZD | +0.65% | -1.59% | -11.71% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.71% | 192M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- AFT Stock
- News AFT Pharmaceuticals Limited
- AFT Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024